Bank of New York Mellon
ZVRA icon

Bank of New York Mellon’s Zevra Therapeutics ZVRA Stock Holding History

Bank of New York Mellon’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
198,432
+26,005
+15% +$289K ﹤0.01% 2750
2026
Q1 		$1.61M Sell
172,427
-1,728
-1% -$15.6K ﹤0.01% 2934
2025
Q4 		$1.56M Buy
174,155
+48,324
+38% +$457K ﹤0.01% 2986
2025
Q3 		$1.2M Buy
125,831
+6,856
+6% +$68.8K ﹤0.01% 3107
2025
Q2 		$1.05M Sell
118,975
-1,458
-1% -$11.8K ﹤0.01% 3106
2025
Q1 		$902K Buy
120,433
+11,946
+11% +$94.9K ﹤0.01% 3130
2024
Q4 		$905K Sell
108,487
-37,365
-26% -$319K ﹤0.01% 3215
2024
Q3 		$1.01M Sell
145,852
-74,647
-34% -$507K ﹤0.01% 3136
2024
Q2 		$1.08M Buy
220,499
+21,231
+11% +$101K ﹤0.01% 3155
2024
Q1 		$1.16M Sell
199,268
-3,505
-2% -$21.5K ﹤0.01% 3072
2023
Q4 		$1.33M Hold
202,773
– – ﹤0.01% 3042
2023
Q3 		$977K Sell
202,773
-110
-0.1% -$549 ﹤0.01% 3161
2023
Q2 		$1.03M Buy
202,883
+88,257
+77% +$476K ﹤0.01% 3181
2023
Q1 		$630K Hold
114,626
– – ﹤0.01% 3371
2022
Q4 		$526K Sell
114,626
-3,540
-3% -$18K ﹤0.01% 3516
2022
Q3 		$738K Hold
118,166
– – ﹤0.01% 3357
2022
Q2 		$527K Sell
118,166
-45,451
-28% -$207K ﹤0.01% 3549
2022
Q1 		$823K Buy
163,617
+76,273
+87% +$485K ﹤0.01% 3427
2021
Q4 		$761K Buy
87,344
+1,890
+2% +$16.9K ﹤0.01% 3547
2021
Q3 		$797K Buy
85,454
+12,809
+18% +$129K ﹤0.01% 3534
2021
Q2 		$931K Buy
+72,645
New +$781K ﹤0.01% 3464
2019
Q1 		– Sell
-1,280
Closed -$36K – 4263
2018
Q4 		$36K Buy
1,280
+193
+18% +$7.81K ﹤0.01% 4100
2018
Q3 		$84K Sell
1,087
-44
-4% -$3.44K ﹤0.01% 4061
2018
Q2 		$118K Sell
1,131
-263
-19% -$25.7K ﹤0.01% 3984
2018
Q1 		$176K Buy
1,394
+122
+10% +$11.8K ﹤0.01% 3958
2017
Q4 		$82K Buy
1,272
+68
+6% +$4.1K ﹤0.01% 4132
2017
Q3 		$71K Hold
1,204
– – ﹤0.01% 4049
2017
Q2 		$77K Sell
1,204
-224
-16% -$14.8K ﹤0.01% 4071
2017
Q1 		$112K Buy
1,428
+213
+18% +$12.9K ﹤0.01% 4003
2016
Q4 		$57K Buy
+1,215
New +$74.6K ﹤0.01% 4115

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Bank of New York Mellon's ZVRA Position: Q2 2026 in Review

Bank of New York Mellon increased its Zevra Therapeutics (ZVRA) stake by 15% in Q2 2026, buying an estimated $289K and bringing the position to 198,432 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

Bank of New York Mellon first reported a position in ZVRA in Q4 2016 and has held it in 30 quarters since. 82 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Bank of New York Mellon held 198,432 shares of Zevra Therapeutics worth $2.85M as of Q2 2026.
  • Bank of New York Mellon bought 26,005 Zevra Therapeutics shares in Q2 2026, an estimated $289K.
  • Zevra Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2750 holding.
  • Bank of New York Mellon first reported a position in Zevra Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • 82 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.